Hallucinogens - Toxicity
Research News and Information

Sunday, November 22, 2009

Modulation of MDMA-induced behavioral and transcriptional effects by the delta opioid antagonist naltrindole in mice.

29 Jun 2009 The delta opioid system is involved in the behavioral effects of various drugs of abuse. However, only a few studies have focused on the possible interactions between the opioid system and the effects of 3,4-methylenedioxymethamphetamine (MDMA). In ... Read more...

(+/-)3,4-Methylenedioxymethamphetamine (MDMA) dose-dependently impairs spatial learning in the morris water maze after exposure of rats to different five-day intervals from birth to postnatal day twenty.

15 Apr 2009 During postnatal days (PD) 11-20, (+/-)3,4-methylenedioxymethamphetamine (MDMA) treatment impairs egocentric and allocentric learning, and reduces spontaneous locomotor activity; however, it does not have these effects during PD 1-10. How the ... Read more...

Dissociation between serotonin neurotoxicity and brain-derived neurotrophic factor induction following neonatal MDMA exposure in rats.

15 Apr 2009 Early developmental treatment of rats with 3,4-methylenedioxymethamphetamine (MDMA) was previously found to cause an abnormal pattern of forebrain serotonergic axon density in adulthood consisting of a cortical hypoinnervation and a striatal ... Read more...

Latest indexed articles for 'Hallucinogens - Toxicity'

These are the very latest articles for this heading:

• Modulation of MDMA-induced behavioral and transcriptional effects by the delta opioid antagonist naltrindole in mice. 29 Jun 2009
• [Ecstasy, new psychotropic drugs] 29 Apr 2009
• (+/-)3,4-Methylenedioxymethamphetamine (MDMA) dose-dependently impairs spatial learning in the morris water maze after exposure of rats to different five-day intervals from birth to postnatal day twenty. 15 Apr 2009
• Dissociation between serotonin neurotoxicity and brain-derived neurotrophic factor induction following neonatal MDMA exposure in rats. 15 Apr 2009
• Recent EEG and ERP findings in substance abusers. 30 Mar 2009
• Effect of delta-9-tetrahydrocannabinol on altered antioxidative enzyme defense mechanisms and lipid peroxidation in mice testes. 30 Mar 2009
• Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats. 22 Mar 2009
• Transcriptomic configuration of mouse brain induced by adolescent exposure to 3,4-methylenedioxymethamphetamine. 8 Mar 2009
• From Amrita to substance D: psychopharmacology, political economy, and technologies of the self. 27 Feb 2009
• Importance of psychiatric confounding in non-randomized studies of heavy ecstasy users. 10 Feb 2009
• Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat. 30 Jan 2009
• The harmful health effects of recreational ecstasy: a systematic review of observational evidence. 30 Dec 2008
• Involvement of inferior parietal lobules in prospective memory impairment during acute MDMA (ecstasy) intoxication: an event-related fMRI study. 15 Dec 2008
• The hyperthermia mediated by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) is sensitive to sex differences. 12 Dec 2008
• Acetyl-L-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. 28 Oct 2008
• Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. 5 Oct 2008
• The phenomenology of the psychotic break and Huxley's trip: substance use and the onset of psychosis. Sep 2008
• Toxic psychosis after intake of the hallucinogen salvinorin A. 30 Aug 2008
• Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion. 30 Aug 2008
• Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. 19 Aug 2008

See a longer list of these articles.

Technical information about 'Hallucinogens'

Definition: Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise.

Registry Number: 0

Descriptor UI: D006213

Alternative terms: Hallucinogens; Psychotomimetic Agents; Agents, Psychotomimetic; Hallucinogenic Agents; Agents, Hallucinogenic; Hallucinogenic Substances; Substances, Hallucinogenic; Psychedelics; Psychedelic Agents; Agents, Psychedelic; Hallucinogenic Drugs; Drugs, Hallucinogenic;

Related Mesh Headings: Hallucinations;

Allowable Qualifiers: chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid;

Tree Number: D27.505.696.388; D27.505.954.427.300; D27.505.954.427.700.372;

Technical Notes: GEN or unspecified; prefer specifics; consider also HALLUCINATIONS /chem ind